10th EPP Life Sciences Pricing Forum 2021 in Munich

Presentation by: PTC Therapeutics 

Edition 2/2021: Tackling The Pharma Path For Optimizing Revenue Streams

Life Science companies are facing unprecedent pricing pressures and commercialed disruption due to the COVID-19 pandemic and subsequent economic crisis. In this difficult time many businesses need to find mechanisms to optimize their revenue streams. In this whitepaper we’ll analyze how moving from operational silos to full visibility helps companies to gain not only control of all their transactional processes but also how to elevate to the next level of maturity and see which decisions to take for maximizing margins. We’ll identify why many companies are stuck in asilo fragmented revenue model where processes are not harmonized and have undetected revenue leakages. Once decided for a holistic revenue management companies can obtain not only full transactional control but also move from reactive to proactive approach to further maximizing profit margins.

The EPP® Thought Leadership Series provide insights from pricing leaders around the globe. When a new insight breaks, these pricing leaders already think of the unanswered questions and the story behind the story.  These people want to inspire you to act - to take the next step in your journey. With these series, we help to take the right actions

10th EPP Life Sciences Pricing Forum 2021 in Munich

Presentation by: CSL Behring

While C-Level executives have huge ambitions in innovating pricing, firms are faced with barriers on their way to implementation. Consider the executives participating in Accenture’s global pricing study. Nearly all (94 percent) see pricing as one of their main strategic priorities. However, only one-third said their company has implemented new pricing approaches widely across the organization. This suggests many companies still aren’t achieving their pricing goals — and that points to shortcomings in implementation and execution.

C-level executives continue to consider pricing a top strategic priority, and for good reason: It’s the largest driver of growth in customers, revenue, and profits.

What’s helped some of today’s most successful companies flourish? A big factor is their pairing of innovative digital offerings with new price models that are fast becoming the focus in every industry B2C and B2B companies,especially some of the most successfulcompanies in media and technology.

New market realities are leading many businesses to the realization that spreadsheets and ERP systems are just not built to handle the levels of pricing performance, scalability, and even complexity needed to accommodate pricing for the modern B2B buyers. This eBook will help you understand the importance of shedding traditional methods of managing price by highlighting 7 key considerations. You'll learn why technologically advanced pricing capabilities will allow you to gain enhanced understanding and control of your dynamic price strategies, so you can succeed in today’s digital commerce marketplace.

C-level executives continue to consider pricing a top strategic priority, and for good reason: It’s the largest driver of growth in customers, revenue, and profits.

In the “old days,” pricing used to be largely a “set it and forget it” exercise. But not anymore. Automated price setting and more frequent price changes to best capture customers’ willingness-to-pay is today’s “holy grail” of pricing for most companies. Pioneered by airlines’ smart revenue management systems, dynamic pricing has gained prominence in many other settings — including hotels, ride hailing, e-commerce and, increasingly, traditional retail. 

In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL).

This year, PD-1 inhibitors — a category of drugs that are often costly yet highly effective — were the hot issue between multinational corporations (MNCs) and domestic businesses. When the negotiations came to a close, home-grown PD-1 efforts from Shanghai Junshi Biosciences, BeiGene Ltd. and Jiangsu Hengrui Medicine took the coveted spots from household names like Roche, Bristol Myers Squibb, AstraZeneca and MSD.

In this whitepaper, Craig Zawada, Chief Visionary Officer of PROS, explains:

• Why digital interactions are the new imperative
• Where B2B companies fall short on digital strategies
• The volatility trifecta
• Recommendations to light up digital channels

C-level executives continue to consider pricing a top strategic priority, and for good reason: It’s the largest driver of growth in customers, revenue, and profits.

New global research from Accenture highlights the current state of pricing as well as where pricing is headed in the near future. They surveyed more than 500 C-level executives in companies with more than US$1 billion in revenue across 17 business-to-business (B2B) and business-to-consumer (B2C) industries in Europe, Asia, and America.